New BEND2 Fusion Gene Flags Aggressive Pancreatic Tumors With Poor Survival
Whole transcriptome sequencing uncovers recurrent BEND2 fusions in pancreatic neuroendocrine tumors, independently predicting worse disease-free and disease-specific survival.
Summary
Researchers used whole transcriptome sequencing on 73 nonfunctional pancreatic neuroendocrine tumors (NF-PanNETs) and discovered recurrent fusion genes involving BEND2, a chromatin remodeling gene. Found in roughly 7% of tumors, BEND2 fusions occurred exclusively in the most aggressive tumor cluster and were independent of previously known risk mutations ATRX and DAXX. Validation across 539 PanNETs confirmed BEND2 protein expression as a reliable surrogate marker. Patients with BEND2-positive tumors had significantly shorter disease-free and disease-specific survival. Combined with ATRX and DAXX alterations, chromatin remodeling disruptions now account for 62% of metastatic NF-PanNETs, pointing to this pathway as a central driver of aggressive disease.
Detailed Summary
Pancreatic neuroendocrine tumors are notoriously unpredictable — some grow slowly for decades while others metastasize rapidly. Identifying molecular markers that distinguish indolent from aggressive tumors is critical for guiding surveillance and treatment decisions, yet many tumors lack known driver mutations.
In this study, researchers applied whole transcriptome sequencing to 73 nonsyndromic nonfunctional PanNETs with more than four years of clinical follow-up. Transcriptomic profiling sorted tumors into six clusters; cluster 6 stood out for high WHO grade, distant metastases, and upregulation of telomere maintenance via telomerase activation. Within this aggressive cluster, recurrent fusion genes involving the chromatin remodeling gene BEND2 — specifically CHD7::BEND2 and EWSR1::BEND2 — were detected in 7% (5/73) of cases, all independent of ATRX and DAXX mutation status.
Validation using immunohistochemistry in an independent multi-institutional cohort of 539 PanNETs confirmed BEND2 protein expression in 3% of cases, all verified to harbor BEND2 fusions by sequencing. Patients with BEND2-positive tumors experienced significantly shorter disease-free survival (P < .001) and disease-specific survival (P < .001). Multivariate analysis confirmed BEND2 as an independent negative prognostic factor, not explained by tumor grade, size, or other known markers.
Broadly, ATRX, DAXX, and BEND2 alterations together were present in 62% of metastatic NF-PanNETs, reinforcing chromatin remodeling and telomere maintenance as central oncogenic pathways in this disease.
Caveats include the retrospective design and the fact that only the abstract was available for review. The relatively small discovery cohort (n=73) and low BEND2 prevalence (3–7%) mean larger prospective studies are needed to fully establish clinical utility. Nevertheless, these findings suggest BEND2 immunohistochemistry could be integrated into routine pathology workups to risk-stratify NF-PanNET patients.
Key Findings
- BEND2 fusion genes (CHD7::BEND2, EWSR1::BEND2) found in 7% of NF-PanNETs via whole transcriptome sequencing.
- BEND2-positive tumors clustered exclusively in the most aggressive transcriptomic group with high grade and metastases.
- BEND2 expression independently predicted shorter disease-free and disease-specific survival on multivariate analysis.
- ATRX, DAXX, and BEND2 alterations together account for 62% of metastatic NF-PanNETs.
- Immunohistochemistry for BEND2 validated in 539 PanNETs, making it a practical clinical biomarker candidate.
Methodology
Whole transcriptome sequencing was performed on 73 nonsyndromic NF-PanNETs with >4 years of clinical follow-up, followed by transcriptomic clustering and gene ontology pathway analysis. Findings were validated by immunohistochemistry in an independent multi-institutional cohort of 539 PanNETs. Survival analyses including Kaplan-Meier and multivariate Cox regression assessed the independent prognostic value of BEND2 expression.
Study Limitations
The discovery cohort was relatively small (n=73) and retrospective, which may limit generalizability and statistical power. Only the abstract was available for full review, restricting assessment of methodological details and potential confounders. The low overall prevalence of BEND2 fusions (3–7%) will require large prospective cohorts to confirm clinical utility and cost-effectiveness of routine testing.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.